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ABSTRACT
Prostaglandin D2 (PGD2) is one of the most abundant lipid mediators present in the airways of asthmatics.
However, little was known of the role it plays in the pathophysiology of asthma, until the identification of DP
(DP1, PTGDR) and CRTH2 (DP2), two PGD2-specific transmembrane receptors with different distribution and
intracellular signaling. Pharmacological tools, such as receptor-specific agonists and antagonists, and
genetically-engineered mice, which lack either DP or CRTH2, have helped understand the complex effects of
PGD2 in allergic inflammation of the airways. Furthermore, genetic association studies have shown a positive
linkage of the genetic polymorphisms in DP and CRTH2, with asthma phenotypes from specific ethnic back-
grounds, further highlighting the importance of PGD2 and its receptors in the pathophysiology of asthma.
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ROLE OF PROSTAGLANDIN D2 IN ASTHMA
Prostaglandin D2 (PGD2) is a major lipid mediator
synthesized from arachidonic acid via the catalytic ac-
tivities of cyclooxygenases (COX) and PGD2 syn-
thases (PGDS) in mast cells, macrophages, and other
cellular sources. In patients suffering from allergic
diseases, such as asthma, the de novo production of
PGD2 is increased during allergen exposure.1,2 In
asthmatics, after an allergen challenge, the concen-
trations of PGD2 are increased in the broncho-
alveolar lavage (BAL) fluid,3 and the concentrations
of 9α, 11β-PGF2, its main metabolite, are increased in
plasma and urine.4 An increase in the urinary excre-
tion of 9α, 11β-PGF2 has also been observed after as-
pirin challenge in patients with aspirin-induced
asthma.5
It is generally believed that, in asthmatics, PGD2
modulates the physiology of the airways by causing
bronchoconstriction,6 vasodilation,7 increases in cap-
illary permeability8 or mucous production.9 In addi-
tion, the recent identification of new isoforms of
PGD2 receptors, the development of isoform-specific
receptor agonists and antagonists, and the creation of
genetic mouse models, which lack the specific iso-
form of PGD2 receptors, have helped clarifying the
important roles played by PGD2 and its receptors in
the pathophysiology of asthma, especially its role in
the airway inflammation and bronchial hyperrespon-
siveness. Besides observations made in animal mod-
els, genetic association studies of PGD2-related mole-
cules in humans have also revealed a significant link
between PGD2 and asthma. This review updates our
understanding of the role played by PGD2 in asthma
gathered from animal models and genetic association
studies.
PGD2 METABOLISM
The first step in the production of PGD2, is the libera-
tion of arachidonic acid from phospholipids in cellular
membranes, via the activities of phospholipases, fol-
lowed by its conversion to cyclic endoperoxide PGG2
by COXs.10 Two isoforms of COXs are present in the
airways: COX-1, also known as prostaglandin H syn-
thase 1 (PGHS1) is constitutively expressed and func-
tions as a house keeping gene, while COX-2 (PGHS2)
is induced during inflammation. The peroxydase ac-
tivity of these enzymes transforms PGG2 to PGH2, an
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Fig. 1 Phylogenetic tree of prostanoid receptors and other GPCR for chemoatractants and lipid mediators. The asterisk 
marks the receptors for PGD2 with their selective agonists and antagonists.
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unstable intermediate endoperoxide, which is imme-
diately converted to PGD2 by PGDS.
These are also 2 isoforms of PGDS.11 Hematopoie-
tic PGDS (H-PGDS) is present in mast cells, macro-
phages, and dendritic cells, while lipocalin-type
PGDS (L-PGDS) is mostly expressed in the central
nervous system. Once synthesized, PGD2 is rapidly
metabolized non-enzymatically to 15-deoxy-∆12,14-
PGJ2 (15dPGJ2) or ∆12-PGJ2 depending on the pres-
ence of serum albumin.
PGD2 RECEPTORS ON EOSINOPHILS AND
OTHER INFLAMMATORY CELLS
Recent studies have identified 2 types of trans-
membrane receptors specific for PGD2 expressed on
inflammatory cells, such as eosinophils, basophils,
and lymphocytes. The first, D prostanoid receptor
(DP) is a classic PGD2 receptor also known as
PTGDR or DP112,13; the second is chemoattractant
receptor-homologous molecule expressed on Th2
(CRTH2), also known as DP2.14 Both are members of
the seven-transmembrane-domain, G-protein-coupled
receptor (GPCR) superfamily. DP, which is ex-
pressed ubiquitously, belongs to a GPCR cluster that
includes other prostanoid receptors (Fig. 1),15 and is
coupled with a Gsα protein, which increases the con-
centration of intracellular cAMP.13 In contrast,
CRTH2 is genetically closer to chemotactic receptors,
such as chemokine receptors and the leukotriene B4
receptor (Fig. 1), coupled with Giα protein, which
causes an increase in calcium and a decrease in con-
centrations of cAMP. The expression of CRTH2 is
limited to eosinophils, basophils, and Th2 lympho-
cytes.14
Whether the DP receptor acts as a pro- versus an
anti-inflammatory molecule during allergic inflamma-
tion remains controversial. PGD2 or DP-specific ago-
nists inhibit apoptosis and prolong the survival of
eosinophils. These compounds also block the produc-
tion of interleukin-12 (IL-12) in dendritic cells, biasing
the development of naive T lymphocytes to cells pro-
ducing type 2 cytokines.16,17 PGD2, by the suppress-
ing functions of NK cells, including the production of
Th1 cytokine via DP, can promote the Th2-mediated
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immune response.18 Conversely, DP-specific agonists
inhibit the migration and degranulation of baso-
phils.19
In contrast to DP, the activities of CRTH2 observed
in vitro strongly suggest that CRTH2 acts as a mole-
cule that exacerbates allergic inflammation. CRTH2
agonists induce a marked increase in cell mobility
and degranulation, and increase the expression of ad-
hesion molecules in eosinophils and basophils.14,19-21
PGD2 also increases in a CRTH2-dependent manner
the lymphocytic production of Th2 cytokines, includ-
ing IL-4, -5, and -13.22
Besides DP and CRTH2, PGD2 binds to the
thromboxan A2 receptor, TP, and one of the PGE2 re-
ceptors, EP3. Figure 1 shows the selective agonists
and antagonists identified for these receptors. PGD2
and its cyclopentenone-type metabolites, such as
15dPGJ2, also exert an anti-inflammatory activity, par-
tially via a peroxisome proliferator-activated receptor-
γ (PPAR-γ).23 In low concentrations, 15dPGJ2 pro-
motes the eotaxin-induced chemotaxis of eosinophils
in a PPAR-γ-dependent manner, while, in higher con-
centrations,24 15dPGJ2 directly acts as a ligand for
CRTH2 and activates the eosinophils.23
ROLE OF PGD2 AND ITS RECEPTORS ON
ALLERGIC INFLAMMATION OF THE AIR-
WAYS
We have previously described the COX-2-dependent
synthesis of PGD2 in the lungs of ovalbumin-
sensitized and challenged guinea pigs.25 NS-398, a
COX-2-specific inhibitor, blocked this synthesis, and
inhibited the recruitment of eosinophils into the
lungs. Conversely, others have reported that in-
creased concentrations of PGD2 exacerbated eosino-
philic inflammation of the airways. The intra-tracheal
administration of PGD2 intensified the allergen-
induced eosinophilic inflammation in mice.26 The
over-expression of lipocalin-type PGDS also increased
the concentration of Th2 cytokines, and promoted the
accumulation of eosinophils in the lungs.27 These ob-
servations suggest that PGD2 plays important roles in
allergic inflammation of the airways.
ROLE OF DP
In an allergen-induced asthma model of genetically-
engineered DP-deficient mice, the phenotypes, such
as airway eosinophilia, bronchial hyperresponsive-
ness, and Th2 cytokine responses were all attenu-
ated.28 Furthermore, the expression of DP receptors
were significantly enhanced in the allergen-
stimulated epithelial cells of the airways. The pro-
inflammatory role of DP was further supported by the
inhibition of the accumulation of eosinophils by a DP-
specific antagonist, in sensitized guinea-pig lungs.29
DP receptor antagonists also partially blocked the
PGD2-induced mobilization of eosinophils from the
bone marrow in a perfused, guinea pig hind-limb
preparation.30 However, in recent experiments, the
intratracheal administration of a DP-selective agonist
activated the DP receptors on dendritic cells, in-
creased the number of Foxp3+ CD4+ regulatory T
cells, and suppressed airway inflammation in a IL-10-
dependent manner.31 The infusion of DP agonist-
stimulated dendritic cells similarly suppressed the in-
flammation, while dendritic cells from DP-deficient
mice lacked this activity.
ROLE OF CRTH2
We have observed the induction of airway eosino-
philia in IL-5- or allergen-exposed rodents by the
intra-tracheal administration of PGD2 or CRTH2 ago-
nists, however not by a DP agonist.32,33 This chemo-
tactic activity of CRTH2 agonists on eosinophils in
vivo was confirmed by other investigators.34,35 Fur-
thermore, we and others have shown that ramatro-
ban, a dual receptor blocker for CRTH2 and TP, but
not DP- or TP-specific antagonists, suppressed the
eosinophilia induced by PGD2 or CRTH2 agonists in
the blood and airways.32,33,36 TM30089, a highly
CRTH2-selective antagonist, also inhibited airway
eosinophilia and goblet cell hyperplasia after allergen
challenge.37 It is, thus, surprising that, after allergen
exposure, the eosinophilic inflammation was not at-
tenuated in the airways of CRTH2-deficient mice.33,38
Furthermore, the eosinophilia in allergen-exposed,
CRTH2-deficient mice with a Balbc background was
as pronounced as that observed in wild-type mice.33 It
is particularly noteworthy that, compared with wild-
type mice, CRTH2-deficient mice with a C57BL6
background developed more severe inflammation of
the airways, along with an over-production of IL-3 and
IL-5.38 The observations made with respect to murine
CRTH2 must be interpreted cautiously. Whereas, in
humans, the expression of CRTH2 on T lymphocytes
is limited to Th2 subpopulation and does not include
Th1, murine Th1 and Th2 lymphocytes both express
CRTH2 mRNA.38,39
We have shown, however, that the exacerbation of
airway inflammation induced by the instillation of
double-stranded RNA (which mimics the exacerba-
tion of asthma induced by RNA virus infection), does
not occur in CRTH2-deficient mice.33 A similar sup-
pression of the exacerbation of allergic inflammation
and bronchial hyperresponsiveness induced by
double-stranded RNA was observed with pharma-
cological blockade of CRTH2, which was conserved
among different animal species.33 These observations
point to the discovery of a new role played by the
PGD2-CRTH2 axis in the innate immune response to
viral infection, and to the potential therapeutic appli-
cation of CRTH2 antagonists in the prevention of
asthmatic exacerbations.
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Table 1 Genetic association studies of PGD2-related genes
ReferenceOutcomeEthnic originMutation(s)Gene locusAcronymGene name
40PositiveAsian (Japanese)IVS2 ＋ 11 A ＞ C)4q21-q22PGDSHematopoietic prostaglan-
din D synthase
40NegativeAsian (Japanese)T-197C, C-2T14q22.1DPProstanoid DP receptor
DP1
PTGDR
43PositiveEuropean-American
African-American
T-197C, T-549C, C-441T
47NegativePuerto-Rican; Mexican
African
T-197C, T-549C, C-441T
45PositiveEuropean (UK and Danish)
American
A-731G, G-338A, C6541T,
C6651T
46NegativeAsian (Chinese-Han)T-197C, T-549C, C-441T
44PositiveEuropean; Spanish-AmericanT-197C, T-549C, C-441T
48PositiveAfrican-American,
Asian (Chinese)
G1544C, G1651A,
T11336C, G12375T
11q12-q13.3CRTH2
GPR44
Chemoatractant receptor-
homologous molecule ex-
pressed on Th2 49NegativeAsian (Japanese)G1544C, G1651A,
T11336C, G12375T
Table 2 Haplotypes frequencies of polymorphisms in the promoter lesion of DP
AsianHispanicAfrican-AmericanEuropean-AmericanEthnic origin
Li et al.46Tsai et al.47CombinedTsai et al.47Oguma et al.43CombinedSanz et al.44Oguma et al.43
Control
9922117645254 79175n
Puerto-RicanMexicanHaplotype
31NANA 42 4337 37 39 36CCT
68NANA 30 3028 25 27 24TTT
 0NANA 18 1530 29 22 32TCT
 1NANA 11 12 6  9  9  9CCC
Asthmatic
9933627325617680636118518n
Haplotype
2836 24 42 4243 40 43 39CCT
7132 58 32 3233 27 25 27TTT
 020 11 15 1613＊ 21＊ 19 22＊TCT
 112  7 10 1011 12 12＊ 12＃CCC
＊p ＜ 0.05; ＃p ＝ 0.08; NA ＝ not applicable.
GENETIC ASSOCIATION STUDIES OF PGD2-
RELATED MOLECULES WITH ASTHMA
Several noteworthy associations have been reported
between the genotypes of PGD2-related molecules,
such as PGDS, DP, and CRTH2, and the phenotype
of asthma (Table 1) . The hematopoietic PGDS gene
is located on chromosome 4q22.3. In Japanese chil-
dren, a single nucleotide polymorphism (SNP) in the
second intron of this gene predicted a risk of
asthma.40
The human DP gene is located on chromosome
14q21, where multiple whole-genome linkage analy-
ses have suggested the presence of an asthma-related
region.41,42 Sequencing of the DP gene revealed
three variants (T-549C, C-441T, and T-197C) in the 5’-
flanking region, as well as three variants (C+367A,
G+894A, and G+1044A) in the coding region. We
found that, in both Europeans and African-Americans,
carriers of the C allele of T-549C, or of the T allele of
C-441T, were at higher risk of asthma.43 Further-
more, there was a significant association between
promoter haplotypes of three SNPs in the 5’-flanking
region and susceptibility to asthma. The carriers of
the haplotype with lower promoter activity were less
susceptible to asthma. Our observations were repro-
duced in three different Caucasian populations, in
Spain, the UK, and the Netherlands,44,45 however not
Prostaglandin D2 in Asthma
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in Japanese, Han Chinese, or Hispanics, suggesting
the existence of marked differences among ethnic
groups (Table 2). 46
The haplotype frequency measured in two studies
of Caucasian populations has been consistent (Table
2). The haplotype frequency observed in African-
Americans and Puerto-Ricans was the same as that
found in Caucasians, though significantly different
from that measured in Asians and Mexicans (Table
2). The absence of a Hispanic control population lim-
its the validity of that study .46,47
The human CRTH2 gene is located on chromo-
some11q13. In a case-control study of 2 SNPs,
G1544C and G1651A, in the 3’-untranslated region of
the CRTH2, the allele of 1651G and the haplotype of
1544G-1651G were both significantly associated with
the development of asthma in African-Americans and
in Chinese.48 A functional analysis of experiments
made in vitro suggested that the haplotype of 1544G-
1651G was associated with a higher stability of CRTH
2 mRNA than the 1544C-1651A haplotype.48 The asso-
ciation between CRTH2 gene polymophism and
asthma was, however, not confirmed in a Japanese
population.49
CONCLUSIONS
PGD2 is abundantly present in the airways of asth-
matics. However, its role in the pathophysiology of
asthma remains mysterious because of its multi-
dimensional activity, both pro- and anti-inflammatory.
While the identification of isoforms of the PGD2 re-
ceptors, DP and CRTH2, has solved some of the enig-
mas of the PGD2 story, several issues need to be
clarified before the pharmacological modification of
PGD2 signaling can be applied in therapeutics.
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